Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Finasteride clinical utility continues to be debated

Sep. 6, 1996

Potential BPH therapy from Glaxo Wellcome

Sep. 6, 1996

5alpha-Reductase inhibitors for BPH

Sep. 6, 1996

Roche and Genentech prepare prodrugs of fibrinogen antagonist

Sep. 6, 1996

Thalidomide derivatives as leads for septic shock therapy

Sep. 6, 1996

Arginine analogues for shock

Sep. 6, 1996

CGS-28106 for hypertension and congestive heart failure

Sep. 6, 1996

Zambon selects a dopaminergic compound for evaluation in cardiovascular/renal disorders

Sep. 6, 1996

Orally active dual NK1/NK2 antagonist from Merck & Co.

Sep. 6, 1996

New adenosine A3 receptor antagonist reported at ACS

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...